Pfizer Advances Development of Once-Daily Weight-Loss Pill Danuglipron with Dose Optimization Studies in 2024

Jul 11, 2024, 12:04 PM

Pfizer Inc has announced plans to advance the development of a once-daily formulation of its experimental obesity pill, danuglipron. The company will conduct dose optimization studies in the second half of 2024 following promising pharmacokinetic results from early-stage trials. This move comes after Pfizer scrapped a twice-daily version of the drug late last year. The reworked once-daily modified release version aims to capture a share of the lucrative multibillion-dollar market for obesity medications. Danuglipron is an oral GLP-1 receptor agonist, a class of drugs known for their efficacy in weight loss. Pfizer's decision to proceed with the once-daily formulation reflects its commitment to addressing obesity, a significant public health issue.